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Introduction
Cardiac pacing is an effective treatment option for patients 
with sick sinus syndrome (SSS) and atrioventricular conduc-
tion disorders. During the implantation of permanent pacemak-
er devices, the endocardial right ventricular (RV) pacing lead 
is often positioned at the RV apex. Previous studies have dem-
onstrated that RV pacing (RVP) in patients with dual chamber 
pacemakers (DCPs) can produce long-term deleterious effects 
in the left ventricle (LV) not only in a previously compromised 
LV but also in patients with normal LV function (1, 2). RVP leads 
to abnormal myocardial activation and mimics a left bundle 
branch block with delayed activation of the LV free wall. During 
RVP, the electrical wave front propagates more slowly through 
the myocardium than the physiological recruitment of the His-
Purkinje system, which occurs during sinus rhythm. This leads 
to electrical and mechanical dyssynchrony, with a potential in-
duction of heart failure (HF) and a decrease in cardiac output 
(3, 4). On a cellular level, RVP evokes mitochondrial variations 
and degenerative fibrosis (5). In addition, pacemaker-induced 
cardiomyopathy can lead to regional perfusion abnormalities 
and inadequate oxygen demand (6, 7). Patients with DCPs pre-
senting with reduced LV ejection fraction (LVEF) are often con-
sidered as candidates for biventricular pacemaker or defibril-
lator implantation.
This study retrospectively investigates whether upgrading 
DCP to cardiac resynchronization therapy (CRT) with the addi-
tion of an LV lead improves LV function in patients in whom a re-
duction of LVEF was noticed late after DCP implantation without 
other identifiable causes of underlying heart disease.
Objectives: Right ventricular (RV) pacing induces a left bundle branch block pattern on ECG and may promote heart failure. Patients with dual 
chamber pacemakers (DCPs) who present with progressive reduction in left ventricular ejection fraction (LVEF) secondary to RV pacing are 
candidates for cardiac resynchronization therapy (CRT). This study analyzes whether upgrading DCP to CRT with the additional implantation of 
a left ventricular (LV) lead improves LV function in patients with reduced LVEF following DCP implantation.
Methods: Twenty-two patients (13 males) implanted with DCPs and a high RV pacing percentage (>90%) were evaluated in term of new-onset 
heart failure symptoms. The patients were enrolled in this retrospective single-center study after obvious causes for a reduced LVEF were ex-
cluded with echocardiography and coronary angiography. In all patients, DCPs were then upgraded to biventricular devices. LVEF was analyzed 
with a two-sided t-test. QRS duration and brain natriuretic peptide (BNP) levels were analyzed with the unpaired t-test.
Results: LVEF declined after DCP implantation from 54±10% to 31±7%, and the mean QRS duration was 161±20 ms during RV pacing. NT-pro BNP 
levels were elevated (3365±11436 pmol/L). After upgrading to a biventricular device, a biventricular pacing percentage of 98.1±2% was achieved. 
QRS duration decreased to 108±16 ms and 106±20 ms after 1 and 6 months, respectively. There was a significant increase in LVEF to 38±8% and 
41±11% and a decrease in NT-pro BNP levels to 3088±2326 pmol/L and 1860±1838 pmol/L at 1 and 6 months, respectively. 
Conclusion: Upgrading to CRT may be beneficial in patients with DCPs and heart failure induced by a high RV pacing percentage.
(Anatol J Cardiol 2016; 16: 678-83)
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Methods
German patients from the University Hospital of Aachen, 
Germany, treated between 1997 and 2012 with DCPs because 
of symptomatic bradycardia (SSS, high-grade atrioventricular 
block) for an average period of 5 years were included in this 
retrospective single-center study. They presented with clinical 
symptoms and signs of HF, a high ventricular pacing percentage 
(>90%), and a decrease in LVEF (Table 1). Patients with a recently 
diagnosed reduced LVEF and clear reasons for this impaired 
LVEF, such as the progression of coronary heart disease or a new 
relevant valvular heart disease, were excluded from the study. 
All patients included in the analysis had RV leads positioned in 
the RV apex. DCPs were programmed to DDD pacing mode with 
a lower rate of 60 beats per min (bpm) and with a physiological 
atrioventricular delay. All patients underwent a thorough cardio-
vascular examination, as well as a transthoracic echocardiogra-
phy (TTE) and coronary angiography, to rule out the progression 
of or new onset of a heart disease leading to HF. Coronary artery 
disease was ruled out in 10 patients. Twelve of 22 patients had 
a history of coronary artery disease (Table 1) and angiographi-
cally showed no progress. A relevant valvular heart disease as 
a cause of HF was excluded by echocardiography in all patients. 
In all patients, the reprogramming of the pacemaker device in an 
attempt to reduce the RVP percentage was not possible due to 
an intrinsic ventricular rhythm lower than 30 bpm. All patients 
were optimized on guideline-based HF medication comprising 
angiotensin-converting enzyme inhibitors (ACE-inhibitor), beta-
blockers, diuretics, and mineralocorticoid receptor antagonists. 
All 22 patients had well-controlled arterial hypertension with 
normotensive blood pressure (<135/85 mm Hg) during the hos-
pital stay. This was also confirmed in the daily conducted rou-
tine blood pressure measurements. DCPs were then upgraded 
to biventricular devices with the implantation of an LV lead. In 
addition, 15 of the 22 patients were upgraded to a CRT-defibrilla-
tor device. The CRT pacemaker devices were programmed with 
standard monitor zones for the detection of ventricular arrhyth-
mias (>170 bpm). 
Follow-up
All patients were followed-up at 1, 6, and 12 months after the 
CRT implant. At each follow-up, clinical examination, TTE, 12-
lead ECG, and device interrogation were performed. In addition, 
NT-pro brain natriuretic peptide (BNP) levels were assessed to 
evaluate the severity of HF.
Statistical analysis
Continuous variables were expressed as mean±standard de-
viation. LVEF was analyzed with a two-sided t-test after testing 
with the Shapiro–Wilk method for normal distribution. A p-value 
of <0.05 was considered to be statistically significant. QRS dura-
tion and BNP levels were analyzed with the unpaired t-test due 
to abnormal distribution. 
Results
During a 1-year period in 2014, 2250 patients with implant-
ed pacemakers underwent routine device interrogations in the 
University Hospital of Aachen, Germany. Twenty-two patients 
(13 males, age=71 years) with DCPs and high RVP percentages 
(>90%) were evaluated because of clinical symptoms and signs 
of HF. The average period from DCP implantation to HF onset 
was 5 years (shortest, 2 years; longest, 17 years). LVEF signifi-
cantly declined from the initial 54±10% to 37±7% (p=0.001), and 
the mean QRS duration was 161±20 ms during RVP. Clinical signs 
included dyspnea (NYHA class III) and peripheral edema. As an 
expression of HF, BNP levels were elevated (3365±11436 pmoL/L). 
Twelve patients had coronary artery disease (Table 1). All pa-
tients underwent coronary angiography to exclude an ischemic 
cause of the newly emerged HF. Concomitant diseases included 
arterial hypertension (22/22), diabetes mellitus (5/22), and renal 
function impairment (8/22) with a glomerular filtration rate be-
tween 30 and 50 mL/min. Five patients suffered from 1st degree 
mitral regurgitation.
After other causes of HF were excluded, pacemaker-in-
duced cardiomyopathy was assumed to be the cause for the 
reduced LVEF in these 22 patients. Therefore, all DCPs were 
upgraded to biventricular devices with the implantation of an 
LV lead. Only bipolar electrodes were used. These were posi-
tioned in the posterolateral vein in 16 patients and in the an-
terolateral vein in 6.
Table 1. Baseline characteristics
Number of patients 22
Sex, male/female 13/9
Age, years (average, SD) 71±11
LVEF, % (average, SD) 37±7
Ventricular pacing percentage, % (average, SD) 90±14
Sick Sinus Syndrome 1/22
Brady-tachy Syndrome 11/22
3rd degree atrioventricular block 10/22
Atrial fibrillation 13/22
Coronary heart disease 12/22
Arterial hypertension 22/22






Mineralocorticoid receptor antagonist 22/22
Statin 22/22
Age, LVEF, and ventricular pacing percentage were expressed as mean±standard 
deviation. SD- standard deviation
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Follow-up
Twenty of the 22 patients completed the follow-up. The pa-
tient with the shortest period (2 years) between DCP implanta-
tion and HF onset was admitted to hospital with acute decom-
pensated HF and died 2 weeks after LV lead implantation. One 
patient was lost to follow-up. 
At the 1-month follow-up after CRT upgrade, LVEF significant-
ly increased to mean 38±8% (p=0.005) compared with that before 
LV lead implantation (31±7%). There was a trend toward reduc-
tion in BNP levels from 3365±11436 pmoL/L to 3088±2326 pmoL/L 
(p=0.28). QRS duration decreased from 161±20 ms to 108±16 
ms (Table 2, Fig. 1). A biventricular pacing percentage of 98±2% 
was achieved. One patient with CRT-D had atrial fibrillation at 
the 1-month follow-up. In this patient, the biventricular pacing 
percentage was reduced at 85%; however, this improved to 99% 
after successful cardioversion and the concomitant start of an 
antiarrhythmic therapy with amiodarone. There was an improve-
ment in the symptoms of dyspnea to NYHA class II. 
At the 6-month follow-up, LVEF increased further from 38±8% 
to 41±11% (p=0.01). Under biventricular pacing, QRS duration re-
mained stable compared with that of the 1-month follow-up data 
(106±20 ms) (Table 2). BNP levels significantly decreased from 
3088±2326 pmoL/L to 1860±1838 pmol/L (p=0.02). In 1 patient from 
the CRT-D group, device interrogation detected ventricular tachy-
cardia, which was appropriately identified and treated by the de-
vice with shock delivery. One patient was hospitalized because of 
a stroke in the middle cerebral artery territory after the autono-
mous withdrawal of anticoagulation. This anticoagulation was pre-
scribed in atrial fibrillation with a CHA2DS2-VASc score of 3. For 
preventing thromboembolic stroke in patients with atrial fibrillation 
and a CHA2DS2-VASc score of >2, anticoagulation is mandatory. In 
this case, the patient himself had stopped the oral anticoagulation, 
which unfortunately was leading to a stroke. There was no throm-
bolytic therapy initiated in this patient. Oral anticoagulation with 
warfarin was continued. Fortunately, the patient was discharged 
from the hospital without any residual neurological sequelae.
At the 12-month follow-up, LVEF increased from 41±11% to 
42±8% (p<0.000), and a biventricular pacing percentage of 98±3% 
was maintained. The average QRS duration was 100±11 ms. BNP 
levels significantly decreased from an initial 3365±11436 pmol/L to 
2177±2397 pmol/L (p=0.017); however, there was a slight increase 
compared with the 6-month BNP levels (Fig. 1). Dyspnea improved 
to NYHA class II. Between the 6- and 12-month follow-up, no patient 
suffered from ventricular tachycardia or required ICD therapy. Dur-
ing the duration of the entire follow-up period, no patient received 
inappropriate ICD therapies. In all 20 patients who completed fol-
low-up, no lead complications or device dysfunction occurred.
Subgroup analysis CRT-P
A subgroup analysis performed in 7 CRT-P patients demon-
strated an improvement in LVEF, QRS duration, and BNP levels. 
LVEF before DCP implantation in this group was 59±11%, with a 
QRS duration of 80±12 ms. Before LV lead implantation, LVEF de-
creased to 35±6%, with a QRS duration of 158±15 ms. BNP levels 
were elevated at 2959±2957 pmol/L. 
At the 1-month follow-up, LVEF increased from 35±6% to 
39±7%, with a QRS duration of 96±16 ms. BNP levels were 
3480±2805 pmol/L. At the 6-month follow-up, LVEF improved to 
41±11%, with a QRS duration of 100±21ms. BNP levels decreased 
from 3480±2805 pmol/L to 2401±2805 pmol/L. At the 12-month fol-
low-up, there were no further improvements in the parameters 
assessed. LVEF was 41±6%, QRS duration was 103±9 ms (Fig. 
2a), and BNP levels were 3062±4816 pmol/L (Fig. 2b). Dyspnea 
improved from an initial NYHA class III-IV to NYHA class II at the 
12-month follow-up.
Anatol J Cardiol 2016; 16: 678-83
Table 2. BNP, QRS duration, and left ventricular ejection fraction of all CRT patients at baseline, advent of heart failure, and 1-, 6-, and 12-month follow-up
 Initial pacemaker  Baseline before Follow-up Follow-up Follow-up 
 implantation Bivent upgrade 1 month 6 months 12 months 
 n=22 n=22 n=21 n=12 n=20
BNP, pmol/L (average, SD) – 3365±11436 3088±2326 1860±1838 2177±2397
QRS, ms (average, SD) 80±15 161±20 108±16 106±20 100±11
LV ejection fraction, % (average, SD) 54±10 31±7 38±8 41±11 42±8
Biventricular pacing percentage, % (average, SD) – – 98±2 97±5 98±3





























Figure 1. LVEF was analyzed with a two-sided t-test after testing with 
the Shapiro–Wilk method for normal distribution. A P-value of <0.05 
was considered to be statistically significant
LVEF at initial dual chamber pacemaker implantation, heart failure advent and 1-, 6-, and 
12-month follow-up. ***=P-value<0.005, **=P-value>0.005–0.01
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During the 12-month follow-up, the biventricular pacing 
percentage was maintained at >98%. None of the 7 patients im-
planted with the CRT-P device developed ventricular tachycar-
dia within the programmed monitor zone (>170 bpm) (Table 3). In 
this subgroup, no patients experienced sudden cardiac death. 
None of the CRT-P-patients were treated with antiarrhythmics 
other than beta-blockers.
Discussion
In patients with decreased LV ejection fraction secondary to 
dual pacemaker implantation, an additional implantation of an LV 
pacing lead can significantly reverse LV remodeling, leading to 
an improvement in LV function and reduction in HF. The negative 
effects of high-volume RVP have been previously well described 
(8). RVP is associated with an increased risk of HF, hospitaliza-
tion, and death as described inter alia in the BLOCK-HF-study 
(9). However, data on the incidence of pacemaker-mediated 
cardiomyopathy are inconsistent, and the underlying mecha-
nisms are not yet well understood. In our study, 2250 patients 
were evaluated during a period of 1 year in our pacemaker clin-
ics, during when routine pacemaker checks were performed. Of 
these patients, 22 were identified to have probable pacemaker-
induced cardiomyopathy with clinical symptoms and signs of HF, 
after other possible causes of HF were ruled out. One must also 
take into account that the incidence of pacemaker-induced car-
diomyopathy detected in our study may be conservative as the 
early deterioration of cardiac function often remains clinically 
unrecognized. Previous studies have reported an incidence of 
approximately 9–15% after 1 year of RVP (2, 10). In our study, the 
average time between the implantation of DCPs and advent of 
clinical HF was 5 years; however, we demonstrated that HF can 
present even after 17 years. This was not related to the burden 
of RVP as the RVP percentage in this particular group of patients 
was 100% due to 3rd degree atrioventricular block. The etiology 
for such a late deterioration of LVEF is unclear; however, TTE and 
coronary angiography were performed to rule out other causes 
for new-onset LVEF deterioration, and the patient was optimized 
on medical therapy. On the other hand, the patient with the short-
est period from the implantation of DCPs to advent of clinical HF 
(2 years) was admitted to hospital with acute decompensation 
of HF. This was a 75-year-old woman who had DCP implanted for 
the management of intermittent 3rd degree atrioventricular block. 
An LV lead was implanted due to suspected pacing-induced car-
diomyopathy secondary to this presentation. However, she died 






























































Figure 2. QRS duration and BNP levels were analyzed with the unpaired t-test due to abnormal distribution
(a) QRS duration at heart failure advent and 1-, 6-, and 12-month follow-up. ***=P<0.005, **=P>0.005–0.01, *=P>0.01–0.05. (b) BNP levels at heart failure advent and 1-, 6-, and 12-month follow-up. 
***=P<0.005, **=P>0.005–0.01, *=P>0.01–0.05
Table 3. BNP, QRS duration, and left ventricular ejection fraction of CRT-P patients at baseline, advent of heart failure, and 1-, 6-, and 12-month follow-up
 Initial pacemaker Baseline before Follow-up Follow-up Follow-up 
 implantation CRT-P 1 month 6 month 12 month 
 n=7 n=7 n=5 n=5 n=4
BNP, pmol/L (average, SD) – 2959±2957 3480±2805 2401±2805 3062±4816
QRS, ms (average, SD) 80±12 158±15 96±16 100±21 103±9
LV ejection fraction, % (average, SD) 59±11 35±6 39±7 41±11 41±6
Registration of ventricular tachycardia <170 bpm – – 0 0 0
Biventricular pacing percentage, % (average, SD) – – 99±2 99±1 99±1
The variables were expressed as mean±standard deviation. Bpm - beats per min; SD - standard deviation
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failure 2 weeks after LV lead implantation. This case suggests 
that pacemaker-induced cardiomyopathy can be an acute dis-
ease with fulminant progression. Perhaps an early CRT upgrade 
should be considered in patients with suspected pacemaker-in-
duced cardiomyopathy to prevent such severe progression of HF, 
when the first signs of decreasing LVEF after DCP implantation 
are identified, and vigilant screening may be indicated.
The true incidence of LV remodeling due to RVP is not well 
known. The current data available in literature show that an RVP 
percentage of >40% may be a relevant factor (11). This is con-
sistent with the data from our study, where the RVP percentage 
was >90% in all 22 patients. However, the reasons why some 
pacemaker-dependent patients with a high burden of RVP do not 
develop LV dysfunction remain unclear. We demonstrate that in 
patients with decreased LV ejection fraction secondary to DCP 
implantation and high RVP percentage, the additional implanta-
tion of an LV lead can significantly reverse left ventricular remod-
eling. We used the parameters of BNP level, QRS duration, and 
LVEF as measurements for the effectiveness of CRT. The results 
show a statistically significant improvement of all parameters. 
It was ensured that the patients did not any other drugs except 
for their HF medications. In addition, it appears that optimal HF 
medication therapy itself is insufficient to improve pacemaker-
induced cardiomyopathy in these patients, and the additional 
implantation of an LV lead was the only effective treatment.
A decision of whether patients with suspected pacing-in-
duced HF should be treated with CRT-P or CRT-D was also consid-
ered. The current guidelines (EHRA pacing guidelines) state that 
patients with a reduced LVEF (<35%) and high pacing percentage 
should be recommended for CRT-D therapy (12). However, in these 
patients, CRT-P therapy may be sufficient to increase LVEF over 
the relevant level of 35%. In our study, none of the 7 patients with 
an implanted CRT-P developed ventricular tachycardia within the 
programmed monitor zone (>170 bpm). In addition, in this group of 
CRT-P patients, LVEF increased to >35% (39±7%) at the 1-month 
follow-up (Table 3), to 41±11% at the 6-month follow-up, and to 
41±6% at the 12-month follow-up. Therefore, after only 4 weeks 
of CRT, LVEF significantly increased in patients with suspected 
pacing-induced cardiomyopathy, and there was no longer an in-
dication for a CRT-D device. This is an important consideration 
given the increased peri-procedural and long-term complication 
risks associated with CRT-D devices such as device malfunction, 
infection, and inappropriate ICD therapy secondary to other ar-
rhythmias such as atrial fibrillation (13). In fact, 13 of the 22 pa-
tients in our study suffered from atrial fibrillation. Although none 
of the 15 patients treated with CRT-D experienced inappropriate 
ICD therapies most likely due to complete AV block, this compli-
cation is well known in all ICD patients, and approximately 9.5% 
of all ICD therapies are inappropriate (14). Furthermore, CRT–P 
devices have a substantially better longevity than CRT-D devices 
due to the lower energy consumption and different battery ca-
pacity (15). However, data from larger studies are missing, and 
this will need to be confirmed with further studies (16).
Response to CRT appears to be associated with a favor-
able prognosis. Lower long-term mortality and fewer hospi-
talizations are seen in patients who demonstrate an increase 
in LVEF of ≥30% after CRT (15). Patients with extensive intra-
ventricular conduction disease (long QRS durations) and left 
bundle-branch block are more likely to be responders to CRT. A 
relatively short duration of HF symptoms before CRT implanta-
tion is associated with a better CRT response (17). In a recent 
sub-analysis of our data, all patients with a particularly good 
response to CRT were with a 3rd degree atrioventricular block 
as the initial indication for DCP implantation. Curtis et al. (9) 
already described a good response from patients with a 3rd de-
gree atrioventricular block to CRT. Two patients had stable cor-
onary heart disease, and 7 suffered from dilated cardiomyopa-
thy. Also, the time point for the re-evaluation of patients after 
CRT implantation is important as reverse remodeling takes a 
variable amount of time. Assessment performed too early may 
underestimate the degree of reverse remodeling. However in 
our study, improvements after CRT upgrade could be detected 
after only 1 month, with progressively improved parameters 
seen after 6 months. Interestingly, our study showed no further 
significant LV reverse remodeling at 12 months compared with 
that at 6 months (18).
Study limitations
Even if these results are statistically significant, a shortcom-
ing is the small number of patients and the retrospective nature 
of the study. Our data should be confirmed in a larger prospec-
tive, randomized trial.
Conclusion
In patients with decreased LV ejection fraction secondary 
to dual pacemaker implantation, an additional implantation 
of an LV pacing lead can significantly reverse LV remodel-
ing, leading to improvement in LV function and reduction in 
HF. Thus, inappropriate CRT-D implantation may be avoided. 
We suppose the benefit of CRT in patients with dual chamber 
pacemakers with a high ventricular pacing percentage and 
pacing-induced HF. Our data should be confirmed in a larger 
randomized trial.
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